First Line Ovarian Cancer Treatment - Cohort Study

Non Interventional Study Dealing With the Use of Bevacizumab (Avastin®) in Patients With Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal and Treated in First-line Therapy

The French cooperative group GINECO proposes to implement an observational study to describe a real situation, in daily practice tolerance and methods of administration of bevacizumab (Avastin ®)

Population: Patients aged 18 years and older with an epithelial ovarian cancer, fallopian tube or primary peritoneal or witch it was decided to initiate a process comprising of Bevacizumab (Avastin ®) in first-line therapy

Inclusion Criteria:

• Patients aged 18 years and over,
• Patients with an epithelial ovarian cancer, fallopian tube or peritoneal who will receive bevacizumab (Avastin ®) in first-line therapy
• Patients should be informed of the study orally and should not have any objection their data to be processed.

Exclusion Criteria:

• Patient participation in a clinical trial
• Patient non-affiliated to a social security scheme.